Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference
Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial
Read original at benzinga